Form 4: Merit Medical Systems Director Millner Executes Stock Options and Sells Shares Under 10b5-1 Plan

Director F. Ann Millner of Merit Medical Systems exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan, while also receiving a grant of restricted stock units.

Summary

• On May 15, 2025, F. Ann Millner, a director of Merit Medical Systems Inc., engaged in multiple transactions involving the company's common stock.
• Millner exercised non-qualified stock options to acquire 21,250 shares at a price of $52.17 per share.
• Simultaneously, Millner sold 21,250 shares at a weighted average price of $96.47, with individual sales ranging from $96.16 to $97.16.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on August 7, 2023.
• Additionally, Millner received a grant of 2,152 restricted stock units (RSUs) that will vest on May 15, 2026, contingent upon continued service to the company.
• Following these transactions, Millner beneficially owns 34,543 shares of Merit Medical Systems Inc. common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, and the director maintains a significant stake in the company. There is no indication of unusual or concerning activity.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, suggesting they were planned well in advance and not based on any recent inside information.

Risks

• While the transactions are part of a pre-arranged plan, significant insider selling could potentially create negative market sentiment.

Future Outlook

The director will continue to hold a significant number of shares and has RSUs vesting in the future, indicating a continued stake in the company's performance.

Industry Context

Insider transactions are common, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. Monitoring these transactions provides insights into management's perspective on the company's valuation.

Comparison to Industry Standards

• Comparing the director's trading activity to peers in the medical device industry, such as Medtronic or Boston Scientific, would require analyzing their respective insider transaction filings.
• The use of 10b5-1 plans is widespread among executives in publicly traded companies to manage their stock holdings in a compliant manner.
• The size and frequency of insider transactions can be benchmarked against industry averages to assess whether the activity is typical or unusual.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how the market interprets the insider selling.
• Employees may view the transactions as a standard part of executive compensation and financial planning.

Key Dates

Keywords

Form 4, insider trading, stock options, restricted stock units, 10b5-1 plan, MMSI, Merit Medical Systems, Millner